V710 First-In-Man (FIM) Study (V710-001)

计划入组 124 人 · 首次发布于 2006 年 3 月 15 日

Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004)

计划入组 51 人 · 首次发布于 2009 年 1 月 14 日

V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)

计划入组 40 人 · 首次发布于 2008 年 8 月 15 日

VA10

VB10.COV2

AvR2-V10

Marengo's Invikafusp Alfa Shows Promise in Anti-PD-1 Resistant Solid Tumors

Marengo Secures ESMO 2026 Oral Presentation for Phase 2 Invikafusp Alfa Data in PD-1–Resistant Solid Tumors, Appoints KEYTRUDA Development Leader Eric Rubin to Scientific Advisory Board

Invikafusp Alfa Shows Promise in PD-1 Resistant Solid Tumors